{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:27:37Z","timestamp":1794954457738,"version":"4.9.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The safety and tolerability of histone deacetylase inhibitors (HDACIs) were always a matter of concern. This study aimed to explore the global observational adverse drug reaction (ADR) profiles of the HDACIs: vorinostat, belinostat, panobinostat, pracinostat, entinostat, romidepsin, bufexamac and sodium phenylbutyrate. This study focussed on the investigation whether associations between HDACIs\u2019 ADR profiles and their physicochemical and pharmacological properties exist and how these associations may be harnessed to contribute to safer clinical use. The ADRs of HDACIs were curated from the World Health Organisation (WHO) VigiAccess database (1976\u20132024). Pharmacology data was curated from the chemical database of bioactive molecules with drug-like properties, European Molecular Biology Laboratory (ChEMBL). Physiochemical and pharmacokinetic properties were curated from PubChem, Drug Bank, ChemDraw and FDA new drug application documents for the HDACIs studied. In total, <jats:italic>n<\/jats:italic>\u2009=\u200912,779 ADRs were reported for the selected HDACIs, with <jats:italic>n<\/jats:italic>\u2009=\u200915\/27 of the system organ class (SOC)-related ADRs showing statistical significance (<jats:italic>X<\/jats:italic>\n            <jats:sup>\n              <jats:italic>2<\/jats:italic>\n            <\/jats:sup>, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Vorinostat accounted for <jats:italic>n<\/jats:italic>\u2009=\u20094,225 of the total ADRs, which may be explained by (1) its extensive use in the clinic and (2) it possessed the most clinically achievable off-target pharmacological interactions (<jats:italic>n<\/jats:italic>\u2009=\u20099). This included potent inhibition of the human-ether-\u00e0-go-go-related gene (<jats:italic>h<\/jats:italic>ERG) ion-channel (IC<jats:sub>50<\/jats:sub>\u2009=\u2009322 nM vs. c<jats:sub>max<\/jats:sub> = 1,200 nM), which is likely a contributing factor to the highest rate of cardiac ADRs observed (<jats:italic>n<\/jats:italic>\u2009=\u2009146, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Musculoskeletal ADRs associated with vorinostat\u00a0(<jats:italic>n<\/jats:italic>\u2009=\u200958, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05) can be ascribed to its unique inhibition of HDAC4 (IC<jats:sub>50<\/jats:sub>\u2009=\u2009540 nM vs. c<jats:sub>max<\/jats:sub> = 1,200 nM). The gastrointestinal (GI) ADRs of panobinostat (<jats:italic>n<\/jats:italic>\u2009=\u2009488, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05<jats:italic>)<\/jats:italic> can partly be related to HDAC3 inhibition (IC<jats:sub>50<\/jats:sub>\u2009=\u20092.0 nM vs. C<jats:sub>max<\/jats:sub> = 8.0 nM). The absence of HDAC9 inhibition was unique to entinostat and may explain its beneficial drug reaction in depression (<jats:italic>n<\/jats:italic>\u2009=\u20090 cases). Thrombocytopenia observed with vorinostat, panobinostat and romidepsin may stem from dual inhibition of HDAC1 and HDAC2 and their higher volume of distributions (V<jats:sub>d<\/jats:sub>). Despite all HDACIs having a similar mechanism of action, their unique pharmacology and differing physicochemical and pharmacokinetic properties landscape results in varying ADR profiles.<\/jats:p>","DOI":"10.1038\/s41598-025-19717-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:59:23Z","timestamp":1760453963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adverse drug reaction profiles of histone deacetylase inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruqayyah","family":"Begum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"19717_CR1","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/s41598-024-56855-z","volume":"14","author":"J Komagamine","year":"2024","unstructured":"Komagamine, J. Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study. Sci. Rep. 14 (1), 6058. https:\/\/doi.org\/10.1038\/s41598-024-56855-z (2024).","journal-title":"Sci. Rep."},{"key":"19717_CR2","unstructured":"European Commission. Strengthening pharmacovigilance to reduce adverse effects of medicines. (Accessed 19 December 2024). https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/de\/memo_08_782 (2008)."},{"issue":"4","key":"19717_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.2042-7174.2010.00039.x","volume":"18","author":"C Calder\u00f3n-Ospina","year":"2010","unstructured":"Calder\u00f3n-Ospina, C. & Bustamante-Rojas, C. The DoTS classification is a useful way to classify adverse drug reactions: a preliminary study in hospitalized patients. Int. J. Pharm. Pract. 18 (4), 230\u2013235. https:\/\/doi.org\/10.1111\/j.2042-7174.2010.00039.x (2010).","journal-title":"Int. J. Pharm. Pract."},{"issue":"3","key":"19717_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.mpaic.2022.12.021","volume":"24","author":"M Robinson","year":"2023","unstructured":"Robinson, M. & Amare, M. Adverse drug reactions. Anaesth. Intensive Care. 24 (3), 210\u2013214. https:\/\/doi.org\/10.1016\/j.mpaic.2022.12.021 (2023).","journal-title":"Anaesth. Intensive Care"},{"issue":"12","key":"19717_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1345\/aph.10094","volume":"34","author":"D Suh","year":"2000","unstructured":"Suh, D., Woodall, B. S. & Santis, E. R. H. Clinical and economic impact of adverse drug reactions in hospitalized patients. Sage Journ. 34 (12), 1373\u20131379. https:\/\/doi.org\/10.1345\/aph.10094 (2000).","journal-title":"Sage Journ"},{"issue":"9","key":"19717_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1634\/theoncologist.2018-0476","volume":"24","author":"AH Lavan","year":"2019","unstructured":"Lavan, A. H., O\u2019Mahony, D., Buckley, M., O\u2019Mahony, D. & Gallagher, P. Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. Oncologist 24 (9), 968\u2013967. https:\/\/doi.org\/10.1634\/theoncologist.2018-0476 (2019).","journal-title":"Oncologist"},{"issue":"1","key":"19717_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2476-2431\/2\/1\/00114","volume":"2","author":"S Shrestha","year":"2017","unstructured":"Shrestha, S., Shakya, R., Shrestha, S. & Shakya, S. Adverse drug reaction due to cancer chemotherapy and its financial burden in different hospitals of Nepal. Symbiosis 2 (1), 1\u20137. https:\/\/doi.org\/10.15226\/2476-2431\/2\/1\/00114 (2017).","journal-title":"Symbiosis"},{"issue":"2","key":"19717_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4143\/crt.2021.425","volume":"54","author":"HS Shin","year":"2022","unstructured":"Shin, H. S., Choi, J., Lee, J. & Lee, S. Y. Histone deacetylase as a valuable predictive biomarker and therapeutic target in immunotherapy for Non-Small cell lung cancer. Cancer Res. Treat. 54 (2), 458\u2013468. https:\/\/doi.org\/10.4143\/crt.2021.425 (2022).","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"19717_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1570159X13666151021111609","volume":"14","author":"SA Ganai","year":"2016","unstructured":"Ganai, S. A., Ramadoss, M. & Mahadevan, V. Histone deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr. Neuropharmacol. 14 (1), 55\u201371. https:\/\/doi.org\/10.2174\/1570159X13666151021111609 (2016).","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"19717_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","volume":"17","author":"P Gallinari","year":"2007","unstructured":"Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M. & Steink\u00fchler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell. Res. 17 (1), 195\u2013211. https:\/\/doi.org\/10.1038\/sj.cr.7310149 (2007).","journal-title":"Cell. Res."},{"issue":"1","key":"19717_CR11","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","volume":"69","author":"N Reichert","year":"2012","unstructured":"Reichert, N., Choukrallah, M. A. & Matthias, P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell. Mol. Life Sci. 69 (1), 2173\u20132187. https:\/\/doi.org\/10.1007\/s00018-012-0921-9 (2012).","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"19717_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/ph17050620","volume":"17","author":"A Curcio","year":"2024","unstructured":"Curcio, A., Rocca, R., Alcaro, S. & Artese, A. The histone deacetylase family: structural features and application of combined computational methods. Pharmaceuticals 17 (5), 620. https:\/\/doi.org\/10.3390\/ph17050620 (2024).","journal-title":"Pharmaceuticals"},{"issue":"4","key":"19717_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/ph17040444","volume":"17","author":"B Ahmad","year":"2024","unstructured":"Ahmad, B. et al. Investigating potential cancer therapeutics: insight into histone deacetylases (HDACs) inhibitions. Pharmaceuticals 17 (4), 444. https:\/\/doi.org\/10.3390\/ph17040444 (2024).","journal-title":"Pharmaceuticals"},{"issue":"12","key":"19717_CR14","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","volume":"66","author":"S Geurs","year":"2023","unstructured":"Geurs, S., Clarisse, D., Bosscher, K. D. & D\u2019Hooghe, M. The Zinc-Binding group effect: lessons from Non-Hydroxamic acid Vorinostat analogs. J. Med. Chem. 66 (12), 7698\u20137729. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00226 (2023).","journal-title":"J. Med. Chem."},{"issue":"1","key":"19717_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"L Zhang","year":"2018","unstructured":"Zhang, L., Zhang, J., Jiang, Q., Zhang, L. & Song, W. Zinc binding groups for histone deacetylase inhibitors. J. Enzyme Inhib. Med. Chem. 33 (1), 714\u2013721. https:\/\/doi.org\/10.1080\/14756366.2017.1417274 (2018).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"3","key":"19717_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1568026619666190122144949","volume":"19","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups. Curr. Top. Med. Chem. 19 (3), 223\u2013241. https:\/\/doi.org\/10.2174\/1568026619666190122144949 (2019).","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"19717_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bmcl.2022.128797","volume":"70","author":"K Yue","year":"2022","unstructured":"Yue, K. et al. Comparison of three zinc binding groups for HDAC inhibitors \u2013 A potency, selectivity and enzymatic kinetics study. Bioorg. Med. Chem. Lett. 70 (1), 1\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128797 (2022).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"19717_CR18","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","volume":"87","author":"AD Bondarev","year":"2021","unstructured":"Bondarev, A. D. et al. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br. J. Clin. Pharmacol. 87 (12), 4577\u20134597. https:\/\/doi.org\/10.1111\/bcp.14889 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"19717_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","volume":"59","author":"NJ Porter","year":"2019","unstructured":"Porter, N. J. & Christianson, D. W. Structure, mechanism, and Inhibition of the zinc-dependent histone deacetylases. Curr. Opin. Struct. Biol. 59 (1), 9\u201318. https:\/\/doi.org\/10.1016\/j.sbi.2019.01.004 (2019).","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"2","key":"19717_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00228-015-1967-z","volume":"72","author":"S Mu","year":"2016","unstructured":"Mu, S. et al. Panobinostat PK\/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory multiple myeloma. Eur. J. Clin. Pharmacol. 72 (2), 152\u2013161. https:\/\/doi.org\/10.1007\/s00228-015-1967-z (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"19717_CR21","unstructured":"European Medicines Agency. Bufexamac \u2013 referral. (Accessed 20 December 2024). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/bufexamac (2010)."},{"issue":"1","key":"19717_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jjco\/hyac166","volume":"53","author":"H Iwata","year":"2022","unstructured":"Iwata, H. et al. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. Jpn J. Clin. Oncol. 53 (1), 4\u201315. https:\/\/doi.org\/10.1093\/jjco\/hyac166 (2022).","journal-title":"Jpn J. Clin. Oncol."},{"issue":"6","key":"19717_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cncr.30533","volume":"123","author":"G Garcia-Manero","year":"2018","unstructured":"Garcia-Manero, G. et al. Phase II randomized Double-Blinded study of pracinostat in combination with Azacitidine in patients with untreated Higher-Risk myelodysplastic syndromes. Am. Cancer Soc. 123 (6), 994\u20131002. https:\/\/doi.org\/10.1002\/cncr.30533 (2018).","journal-title":"Am. Cancer Soc."},{"key":"19717_CR24","unstructured":"NICE | the National Institute for Health and Care Excellence. (Accessed 20 December 2024). https:\/\/www.nice.org.uk\/\u200c (2021)"},{"issue":"23","key":"19717_CR25","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, O. A. et al. Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33 (23), 2492\u20132499. https:\/\/doi.org\/10.1200\/JCO.2014.59.2782 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"19717_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S2352-3026(16)30147-8","volume":"3","author":"JF San-Miguel","year":"2016","unstructured":"San-Miguel, J. F. et al. Overall survival of patients with relapsed multiple myeloma treated with Panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 3 (11), 506\u2013515. https:\/\/doi.org\/10.1016\/S2352-3026(16)30147-8 (2016).","journal-title":"Lancet Haematol."},{"issue":"11","key":"19717_CR27","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/ATVBAHA.121.316808","volume":"41","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. Pan-HDAC (Histone Deacetylase) inhibitors increase susceptibility of thoracic aortic aneurysm and dissection in mice. Arterioscler. Thromb. Vasc Biol. 41 (11), 2848\u20132850. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316808 (2021).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"1","key":"19717_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/tsaco-2019-000321","volume":"4","author":"UF Bhatti","year":"2019","unstructured":"Bhatti, U. F. et al. Comparative analysis of isoform-specific and non-selective histone deacetylase inhibitors in attenuating the intestinal damage after hemorrhagic shock. Trauma. Surg. Acute Care Open. 4 (1), 1\u20139. https:\/\/doi.org\/10.1136\/tsaco-2019-000321 (2019).","journal-title":"Trauma. Surg. Acute Care Open."},{"issue":"6","key":"19717_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1081\/clt-120014645","volume":"40","author":"MD Sztajnkrycer","year":"2002","unstructured":"Sztajnkrycer, M. D. Valproic acid toxicity: overview and management. J. Toxicol. Clin. Toxicol. 40 (6), 789\u2013801. https:\/\/doi.org\/10.1081\/clt-120014645 (2002).","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"19717_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.26.24304895","author":"B Phillips","year":"2024","unstructured":"Phillips, B., Evans, I., Skerrett, V. & Jones, A. M. United Kingdom National register study of Anti-Epileptic medications: suspected foetal congenital and Pregnancy-Associated side effects. MedRxiv https:\/\/doi.org\/10.1101\/2024.03.26.24304895 (2024).","journal-title":"MedRxiv"},{"issue":"681","key":"19717_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3399\/bjgp19X701897","volume":"69","author":"LV Watkins","year":"2019","unstructured":"Watkins, L. V., Cock, H. R., Angus-Leppan, H. & Shankar, R. Valproate and the pregnancy prevention programme: exceptional circumstances. Br. J. Gen. Pract. 69 (681), 166\u2013167. https:\/\/doi.org\/10.3399\/bjgp19X701897 (2019).","journal-title":"Br. J. Gen. Pract."},{"issue":"1","key":"19717_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13023-019-1064-y","volume":"14","author":"J Clayton-Smith","year":"2019","unstructured":"Clayton-Smith, J. et al. Diagnosis and management of individuals with fetal valproate spectrum disorder; a consensus statement from the European reference network for congenital malformations and intellectual disability. Orphanet J. Rare Dis. 14 (1), 180. https:\/\/doi.org\/10.1186\/s13023-019-1064-y (2019).","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"19717_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/adc.2009.176990","volume":"96","author":"C Cummings","year":"2011","unstructured":"Cummings, C., Stewart, M., Stevenson, M., Morrow, J. & Nelson, J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch. Dis. Child. 96 (7), 643\u2013647. https:\/\/doi.org\/10.1136\/adc.2009.176990 (2011).","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"19717_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-023-01531-8","volume":"15","author":"G Lu","year":"2023","unstructured":"Lu, G. et al. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL). Clin. Epigenetics. 15 (1), 1\u201319. https:\/\/doi.org\/10.1186\/s13148-023-01531-8 (2023).","journal-title":"Clin. Epigenetics"},{"issue":"5","key":"19717_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang, P., Wng, Z. & Liu, J. Role of HDACs in normal and malignant hematopoiesis. Mol. Cancer. 19 (5), 1\u201321. https:\/\/doi.org\/10.1186\/s12943-019-1127-7 (2020).","journal-title":"Mol. Cancer"},{"issue":"13","key":"19717_CR36","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","volume":"23","author":"DT Vogl","year":"2019","unstructured":"Vogl, D. T. et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin. Cancer Res. 23 (13), 3307\u20133315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2526 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"19717_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RS Shah","year":"2019","unstructured":"Shah, R. S. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 42 (2), 235\u2013245. https:\/\/doi.org\/10.1007\/s40264-018-0773-9 (2019).","journal-title":"Drug Saf."},{"issue":"2","key":"19717_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/jnc.14144","volume":"143","author":"BS Durham","year":"2017","unstructured":"Durham, B. S., Grigg, R. & Wood, I. C. Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism. J. Neurochem. 143 (2), 147\u2013256. https:\/\/doi.org\/10.1111\/jnc.14144 (2017).","journal-title":"J. Neurochem"},{"issue":"1","key":"19717_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbagrm.2017.12.002","volume":"1861","author":"C Yanginlar","year":"2018","unstructured":"Yanginlar, C. & Logie, C. HDAC11 is a regulator of diverse immune functions. Biochim. Biophys. Acta Gene Regul. Mech. 1861 (1), 54\u201359. https:\/\/doi.org\/10.1016\/j.bbagrm.2017.12.002 (2018).","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"issue":"7","key":"19717_CR40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.chembiol.2022.05.008","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Andrade, R., Hanna, A. A. & Pflum, M. K. H. Evidence that HDAC7 acts as an epigenetic reader of AR acetylation through NCoR-HDAC3 dissociation. Cell. Chem. Biol. 29 (7), 1162\u20131173. https:\/\/doi.org\/10.1016\/j.chembiol.2022.05.008 (2022).","journal-title":"Cell. Chem. Biol."},{"issue":"5","key":"19717_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s13402-021-00626-9","volume":"44","author":"C Yang","year":"2021","unstructured":"Yang, C., Croteau, S. & Hardy, P. Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer. Cell. Oncol. 44 (5), 997\u20131017. https:\/\/doi.org\/10.1007\/s13402-021-00626-9 (2021).","journal-title":"Cell. Oncol."},{"issue":"9","key":"19717_CR42","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1021\/acs.jmedchem.8b01936","volume":"62","author":"M G\u00e9raldy","year":"2019","unstructured":"G\u00e9raldy, M. et al. Selective Inhibition of histone deacetylase 10: hydrogen bonding to the gatekeeper residue is implicated. J. Med. Chem. 62 (9), 4426\u20134443. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01936 (2019).","journal-title":"J. Med. Chem."},{"issue":"11","key":"19717_CR43","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1007\/s11064-024-04237-2","volume":"49","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Correction to: Histone deacetylase inhibitor RGFP109 overcomes Temozolomide resistance by blocking NF-\u03baB-Dependent transcription in glioblastoma cell lines. Neurochem Res. 49 (11), 3176\u20133178. https:\/\/doi.org\/10.1007\/s11064-024-04237-2 (2024).","journal-title":"Neurochem Res."},{"issue":"8","key":"19717_CR44","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","volume":"103","author":"W Li","year":"2024","unstructured":"Li, W., Fu, Y. & Wang, W. A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors. Ann. Hematol. 103 (8), 3207\u20133217. https:\/\/doi.org\/10.1007\/s00277-024-05691-2 (2024).","journal-title":"Ann. Hematol."},{"key":"19717_CR45","unstructured":"DrugBank Online. Database for Drug and Drug Target Info.  (Accessed 26 December 2024). https:\/\/go.drugbank.com\/drugs\/DB02546"},{"key":"19717_CR46","unstructured":"ChEMBL Database. (Accessed 20 December 2024). https:\/\/www.ebi.ac.uk\/chembl\/"},{"issue":"2","key":"19717_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrd4163","volume":"13","author":"AL Hopkins","year":"2014","unstructured":"Hopkins, A. L., Keser\u00fc Gm, Leeson, P. D., Rees, D. C. & Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13 (2), 105\u2013121. https:\/\/doi.org\/10.1038\/nrd4163 (2014).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"6","key":"19717_CR48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/prp2.1029","volume":"10","author":"L Jones","year":"2022","unstructured":"Jones, L. & Jones, A. M. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): can polypharmacology help explain? Pharmacol. Res. Perspect. 10 (6), 1029. https:\/\/doi.org\/10.1002\/prp2.1029 (2022).","journal-title":"Pharmacol. Res. Perspect."},{"key":"19717_CR49","unstructured":"Zolinza (vorinostat) capsules label. FDA Reference ID: 3043460.  (Accessed 27 December 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021991s002lbl.pdf (2011)."},{"key":"19717_CR50","unstructured":"Romidepsin Injection label. FDA Reference ID: 4575263.  (Accessed 27 December 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/208574Orig1s000,Orig2s000Approv.pdf (2020)."},{"key":"19717_CR51","unstructured":"PHEBURANE\u00ae (sodium phenylbutyrate) oral pellets label. FDA Reference ID: 5000442.  (Accessed 27 December 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216513s000lbl.pdf (2022)."},{"key":"19717_CR52","unstructured":"Electronic Medicines Compendium. Home-Electronic Medicines Compendium (EMC).  (Accessed 26 December 2024). https:\/\/www.medicines.org.uk\/emc\/"},{"key":"19717_CR53","unstructured":"National Library of Medicine. (PubChem, accessed 26 December 2024) https:\/\/pubchem.ncbi.nlm.nih.gov\/"},{"issue":"78","key":"19717_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-020-00953-2","volume":"8","author":"AS Gunter","year":"2020","unstructured":"Gunter, A. S. et al. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol. Commun. 8 (78), 1\u201321. https:\/\/doi.org\/10.1186\/s40478-020-00953-2 (2020).","journal-title":"Acta Neuropathol. Commun."},{"issue":"5","key":"19717_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s002800000256","volume":"47","author":"S Berg","year":"2001","unstructured":"Berg, S. et al. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother. Pharmacol. 47 (5), 385\u2013390. https:\/\/doi.org\/10.1007\/s002800000256 (2001).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"22","key":"19717_CR56","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/blood.V114.22.3780.3780","volume":"114","author":"MS Praz","year":"2009","unstructured":"Praz, M. S. et al. Population pharmacokinetics of Panobinostat (LBH589) in patients with advanced solid tumors and hematologic malignancies following intravenous and oral administration. Blood 114 (22), 3780. https:\/\/doi.org\/10.1182\/blood.V114.22.3780.3780 (2009).","journal-title":"Blood"},{"issue":"11","key":"19717_CR57","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1310\/hjp4911-1009","volume":"49","author":"WL Piper","year":"2014","unstructured":"Piper, W. L., Waddell, J. A. & Solimmando, D. A. Drug monographs: Belinostat and idelalisib. Hosp. Pharm. 49 (11), 1009\u20131013. https:\/\/doi.org\/10.1310\/hjp4911-1009 (2014).","journal-title":"Hosp. Pharm."},{"issue":"5","key":"19717_CR58","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/neuonc\/nor017","volume":"13","author":"FM Iwamoto","year":"2011","unstructured":"Iwamoto, F. M. et al. A phase I\/II trial of the histone deacetylase inhibitor Romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03\u201303. Neuro Oncol. 13 (5), 509\u2013516. https:\/\/doi.org\/10.1093\/neuonc\/nor017 (2011).","journal-title":"Neuro Oncol."},{"key":"19717_CR59","unstructured":"VigiAccess. World Health Organisation.  (Accessed 14 October 2024). https:\/\/www.vigiaccess.org\/"},{"key":"19717_CR60","doi-asserted-by":"publisher","unstructured":"McHugh, M. L. The chi-square test of independence. Biochem Med. 23(2), 143\u201349. https:\/\/doi.org\/10.11613\/bm.2013.018 (2013).","DOI":"10.11613\/bm.2013.018"},{"issue":"1","key":"19717_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00280-004-0766-5","volume":"54","author":"SL Berg","year":"2004","unstructured":"Berg, S. L. et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother. Pharmacol. 54 (1), 85\u201388. https:\/\/doi.org\/10.1007\/s00280-004-0766-5 (2004).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"17","key":"19717_CR62","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.3390\/molecules26175151","volume":"26","author":"A Fr\u00fchauf","year":"2021","unstructured":"Fr\u00fchauf, A. & Meyer-Almes, F. J. Non-Hydroxamate Zinc-Binding groups as warheads for histone deacetylases. Molecules 26 (17), 5151. https:\/\/doi.org\/10.3390\/molecules26175151 (2021).","journal-title":"Molecules"},{"issue":"34","key":"19717_CR63","doi-asserted-by":"publisher","first-page":"21843","DOI":"10.1021\/acsomega.1c03628","volume":"6","author":"A Citarella","year":"2021","unstructured":"Citarella, A., Moi, D., Pinzi, L., Bonanni, D. & Rastelli, G. Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications. ACS Omega. 6 (34), 21843\u201321849. https:\/\/doi.org\/10.1021\/acsomega.1c03628 (2021).","journal-title":"ACS Omega"},{"issue":"3","key":"19717_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1039\/D3CB00222E","volume":"5","author":"D Hayward","year":"2024","unstructured":"Hayward, D. & Beekman, A. M. Strategies for converting turn-motif and Cyclic peptides to small molecules for targeting protein\u2013protein interactions. RSC Chem. Biol. 5 (3), 198\u2013202. https:\/\/doi.org\/10.1039\/D3CB00222E (2024).","journal-title":"RSC Chem. Biol."},{"issue":"15","key":"19717_CR65","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/emboj.2010.136","volume":"29","author":"RH Wilting","year":"2010","unstructured":"Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29 (15), 2586\u20132597. https:\/\/doi.org\/10.1038\/emboj.2010.136 (2010).","journal-title":"EMBO J."},{"issue":"2","key":"19717_CR66","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bcp.15015","volume":"88","author":"D Sandhu","year":"2021","unstructured":"Sandhu, D., Antolin, A. A., Cox, A. R. & Jones, A. M. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. Br. J. Clin. Pharmacol. 88 (2), 742\u2013752. https:\/\/doi.org\/10.1111\/bcp.15015 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"19717_CR67","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","volume":"123","author":"MM Mita","year":"2020","unstructured":"Mita, M. M. & Mita, A. C. Bromodomain inhibitors a decade later: a promise unfulfilled? Br. J. Cancer. 123 (12), 1713\u20131714. https:\/\/doi.org\/10.1038\/s41416-020-01079-x (2020).","journal-title":"Br. J. Cancer"},{"issue":"10","key":"19717_CR68","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/1535-7163.MCT-23-0065","volume":"22","author":"EP Hamilton","year":"2023","unstructured":"Hamilton, E. P. et al. First-in-human study of AZD5153, A Small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma. Mol. Cancer Ther. 22 (10), 1154\u20131165. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0065 (2023).","journal-title":"Mol. Cancer Ther."},{"issue":"50","key":"19717_CR69","doi-asserted-by":"publisher","first-page":"18073","DOI":"10.1073\/pnas.1414945111","volume":"111","author":"DK Jones","year":"2014","unstructured":"Jones, D. K. et al. hERG 1b is critical for human cardiac repolarization. PNAS 111 (50), 18073\u201318077. https:\/\/doi.org\/10.1073\/pnas.1414945111 (2014).","journal-title":"PNAS"},{"issue":"2","key":"19717_CR70","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.vascn.2005.07.003","volume":"53","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann, P. & Warner, B. Are hERG channel Inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods. 53 (2), 87\u2013105. https:\/\/doi.org\/10.1016\/j.vascn.2005.07.003 (2006).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"19717_CR71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2008.05.009","volume":"119","author":"JC Hancox","year":"2008","unstructured":"Hancox, J. C. et al. The hERG potassium channel and hERG screening for drug-induced Torsades de pointes. Pharmacol. Ther. 119 (2), 118\u2013132. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.05.009 (2008).","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"19717_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13395-018-0153-2","volume":"8","author":"E Pigna","year":"2018","unstructured":"Pigna, E. et al. HDAC4 preserves skeletal muscle structure following long-term denervation by mediating distinct cellular responses. Skelet. Muscle. 8 (6), 1\u201316. https:\/\/doi.org\/10.1186\/s13395-018-0153-2 (2018).","journal-title":"Skelet. Muscle"},{"issue":"5","key":"19717_CR73","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3892\/mmr.2020.11465","volume":"22","author":"G Du","year":"2020","unstructured":"Du, G. et al. Histone deacetylase 4 deletion results in abnormal chondrocyte hypertrophy and premature ossification from collagen type 2\u03b11expressing cells. Mol. Med. Rep. 22 (5), 4031\u20134040. https:\/\/doi.org\/10.3892\/mmr.2020.11465 (2020).","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"19717_CR74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","volume":"11","author":"T Iannitti","year":"2012","unstructured":"Iannitti, T. & Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 11 (3), 227\u2013249. https:\/\/doi.org\/10.2165\/11591280-000000000-00000 (2012).","journal-title":"Drugs R D"},{"issue":"1","key":"19717_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-022-05298-3","volume":"22","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y., Dou, X., Zhang, C., He, R. & Ding, Y. Hyperammonemia in a pregnant woman with citrullinemia type I: a case report and literature review. BMC Pregnancy Childbirth. 22 (1), 1\u20138. https:\/\/doi.org\/10.1186\/s12884-022-05298-3 (2022).","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"19717_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ogrm.2019.10.002","volume":"30","author":"M Lokman","year":"2020","unstructured":"Lokman, M. & Fitzgerald, C. The effect of cancer on reproductive health. Obstet. Gynecol. Reprod. Med. 30 (1), 6\u201310. https:\/\/doi.org\/10.1016\/j.ogrm.2019.10.002 (2020).","journal-title":"Obstet. Gynecol. Reprod. Med."},{"issue":"4","key":"19717_CR77","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","volume":"60","author":"AK Bubna","year":"2015","unstructured":"Bubna, A. K. Vorinostat- an overview. Indian J. Dermatol. 60 (4), 419. https:\/\/doi.org\/10.4103\/0019-5154.160511 (2015).","journal-title":"Indian J. Dermatol."},{"key":"19717_CR78","unstructured":"FDA: Center for Drug Evaluation and Research. Drug approval package. Clinical Pharmacology and Biopharmaceutics Review(s).  (Accessed 31 December 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205353Orig1s000PharmR.pdf (2014)."},{"key":"19717_CR79","unstructured":"BELEODAQ (belinostat) for injection label. FDA Reference ID: 3536712.  (Accessed 31 December 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf (2014)."},{"issue":"10","key":"19717_CR80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00018-023-04945-y","volume":"80","author":"Y Dai","year":"2023","unstructured":"Dai, Y. et al. Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours by inhibiting ANXA2 degradation. Cell. Mol. Life Sci. 80 (10), 289. https:\/\/doi.org\/10.1007\/s00018-023-04945-y (2023).","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"19717_CR81","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.bbrc.2018.07.043","volume":"503","author":"S Lu","year":"2018","unstructured":"Lu, S., Li, H., Li, K. & Fan, X. D. HDAC9 promotes brain ischemic injury by provoking I\u03baB\u03b1\/NF-\u03baB and MAPKs signaling pathways. Biochem. Biophys. Res. Commun. 503 (3), 1322\u20131329. https:\/\/doi.org\/10.1016\/j.bbrc.2018.07.043 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"19717_CR82","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.biopsych.2006.10.019","volume":"62","author":"M Zhao","year":"2007","unstructured":"Zhao, M. et al. Fibroblast growth factor Receptor-1 is required for Long-Term potentiation, memory consolidation, and neurogenesis. Biol. Psychiatry. 62 (5), 381\u2013390. https:\/\/doi.org\/10.1016\/j.biopsych.2006.10.019 (2007).","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"19717_CR83","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcdb.2015.10.003","volume":"53","author":"CA Turner","year":"2016","unstructured":"Turner, C. A., Eren-Ko\u00e7ak, E., Inui, E. G., Watson, S. J. & Akil, H. Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders. Semin Cell. Dev. Biol. 53 (1), 136\u2013143. https:\/\/doi.org\/10.1016\/j.semcdb.2015.10.003 (2016).","journal-title":"Semin Cell. Dev. Biol."},{"issue":"8","key":"19717_CR84","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1007\/s12035-021-02367-0","volume":"58","author":"L Klimaschewski","year":"2021","unstructured":"Klimaschewski, L. & Claus, P. Fibroblast growth factor signalling in the diseased nervous system. Mol. Neurobiol. 58 (8), 3884\u20133903. https:\/\/doi.org\/10.1007\/s12035-021-02367-0 (2021).","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"19717_CR85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbr.2014.01.053","volume":"264","author":"LR Brooks","year":"2014","unstructured":"Brooks, L. R. et al. Fibroblast growth factor deficiencies impact anxiety-like behavior and the serotonergic system. Behav. Brain Res. 264 (1), 74\u201381. https:\/\/doi.org\/10.1016\/j.bbr.2014.01.053 (2014).","journal-title":"Behav. Brain Res."},{"issue":"25","key":"19717_CR86","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1021\/acs.jafc.9b01968","volume":"67","author":"X Zhu","year":"2019","unstructured":"Zhu, X., Akiyama, T., Yokoyama, T. & Matsumoto, Y. Stereoselective formation of \u03b2-O-4 structures mimicking softwood lignin biosynthesis: effects of solvent and the structures of Quinone Methide lignin models. J. Agric. Food Chem. 67 (25), 6950\u20136961. https:\/\/doi.org\/10.1021\/acs.jafc.9b01968 (2019).","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"19717_CR87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/138527281801140121123046","volume":"18","author":"JL Bolton","year":"2014","unstructured":"Bolton, J. L. Quinone Methide bioactivation pathway: contribution to toxicity and\/or cytoprotection?? Curr. Org. Chem. 18 (1), 61\u201369. https:\/\/doi.org\/10.2174\/138527281801140121123046 (2014).","journal-title":"Curr. Org. Chem."},{"issue":"2","key":"19717_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0009-2797(93)90117-H","volume":"86","author":"DC Thompson","year":"1993","unstructured":"Thompson, D. C., Thompson, J. A., Sugumaran, M. & Mold\u00e9us, P. Biological and toxicological consequences of Quinone Methide formation. Chem. Biol. Interact. 86 (2), 129\u2013162. https:\/\/doi.org\/10.1016\/0009-2797(93)90117-H (1993).","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"19717_CR89","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/onco.13552","volume":"26","author":"ME Lacouture","year":"2021","unstructured":"Lacouture, M. E. et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 26 (2), 316\u2013326. https:\/\/doi.org\/10.1002\/onco.13552 (2021).","journal-title":"Oncologist"},{"issue":"10","key":"19717_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. & Verstovsek, S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell. Rep. Med. 4 (10), 1\u201313. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204 (2023).","journal-title":"Cell. Rep. Med."},{"key":"19717_CR91","unstructured":"Cancer Research, U. K. The immune system and cancer.  (Accessed 01 January 2025). https:\/\/www.cancerresearchuk.org\/about-cancer\/what-is-cancer\/body-systems-and-cancer\/the-immune-system-and-cancer (2023)."},{"issue":"2","key":"19717_CR92","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/jmcb\/mjy035","volume":"11","author":"Q Yang","year":"2019","unstructured":"Yang, Q. et al. Host HDAC4 regulates the antiviral response by inhibiting the phosphorylation of IRF3. J. Mol. Cell. Biol. 11 (2), 158\u2013169. https:\/\/doi.org\/10.1093\/jmcb\/mjy035 (2019).","journal-title":"J. Mol. Cell. Biol."},{"issue":"24","key":"19717_CR93","doi-asserted-by":"publisher","first-page":"11997","DOI":"10.1073\/pnas.1816399116","volume":"116","author":"Y Lu","year":"2019","unstructured":"Lu, Y., Stuart, J. H., Talbot-Cooper, C. & Smith, G. L. Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. PNAS 116 (24), 11997\u201312006. https:\/\/doi.org\/10.1073\/pnas.1816399116 (2019).","journal-title":"PNAS"},{"issue":"9","key":"19717_CR94","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1111\/jcmm.12595","volume":"19","author":"L Poralla","year":"2015","unstructured":"Poralla, L. et al. Histone deacetylase 5 regulates the inflammatory response of macrophages. J. Cell. Mol. Med. 19 (9), 2162\u20132171. https:\/\/doi.org\/10.1111\/jcmm.12595 (2015).","journal-title":"J. Cell. Mol. Med."},{"issue":"3","key":"19717_CR95","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/prp2.603","volume":"8","author":"CJ Ferro","year":"2020","unstructured":"Ferro, C. J., Solkhan, F., Jalal, Z., Al-Hamid, A. M. & Jones, A. M. Relevance of physicochemical properties and functional Pharmacology data to predict the clinical safety profile of direct oral anticoagulants. Pharmacol. Res. Perspect. 8 (3), 603. https:\/\/doi.org\/10.1002\/prp2.603 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2","key":"19717_CR96","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SPC.0000000000000266","volume":"11","author":"RL Stansborough","year":"2017","unstructured":"Stansborough, R. L. & Gibson, R. J. Proteasome inhibitor-induced Gastrointestinal toxicity. Support Palliat. Care. 11 (2), 133\u2013137. https:\/\/doi.org\/10.1097\/SPC.0000000000000266 (2017).","journal-title":"Support Palliat. Care"},{"issue":"1","key":"19717_CR97","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1007018212822","volume":"202","author":"U Bandyopadhyay","year":"1999","unstructured":"Bandyopadhyay, U., Biswas, K., Bandyopadhyay, D., Ganguly, C. & Banerjee, R. Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase - two important gastroprotective enzymes. Mol. Cell. Biol. 202 (1), 31\u201336. https:\/\/doi.org\/10.1023\/A:1007018212822 (1999).","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"19717_CR98","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.celrep.2017.04.046","volume":"19","author":"N Navabi","year":"2017","unstructured":"Navabi, N. et al. Epithelial histone deacetylase 3 instructs intestinal immunity by coordinating local lymphocyte activation. Cell. Rep. 19 (6), 1165\u20131175. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.046 (2017).","journal-title":"Cell. Rep."},{"issue":"6","key":"19717_CR99","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/phar.1396","volume":"34","author":"PM Reynolds","year":"2014","unstructured":"Reynolds, P. M., MacLauren, R., Mueller, S. W., Fish, D. N. & Kiser, T. H. Management of extravasation injuries: A focused evaluation of noncytotoxic medications. Pharmacother 34 (6), 617\u2013632. https:\/\/doi.org\/10.1002\/phar.1396 (2014).","journal-title":"Pharmacother"},{"issue":"7","key":"19717_CR100","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","volume":"10","author":"C Grant","year":"2019","unstructured":"Grant, C. et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 10 (7), 997\u20131008. https:\/\/doi.org\/10.1586\/era.10.88 (2019).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"20B","key":"19717_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/jpri\/2022\/v34i20B35827","volume":"34","author":"A Adil","year":"2022","unstructured":"Adil, A., Malik, M., Malik, J. A., Nazir, S. & Ali, I. S. Down regulation in glutathione S-Transferase stimulate oxidative stress and genetic susceptibility of human breast cancer. J. Pharm. Res. Int. 34 (20B), 1\u201315. https:\/\/doi.org\/10.9734\/jpri\/2022\/v34i20B35827 (2022).","journal-title":"J. Pharm. Res. Int."},{"issue":"1","key":"19717_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-85688-3","volume":"11","author":"X Wu","year":"2021","unstructured":"Wu, X. et al. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci. Rep. 11 (1), 1\u201313. https:\/\/doi.org\/10.1038\/s41598-021-85688-3 (2021).","journal-title":"Sci. Rep."},{"issue":"7","key":"19717_CR103","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","volume":"46","author":"P Garc\u00eda-Abeijon","year":"2023","unstructured":"Garc\u00eda-Abeijon, P. et al. Factors associated with underreporting of adverse drug reactions by health care professionals: A systematic review update. Drug Saf. 46 (7), 625\u2013636. https:\/\/doi.org\/10.1007\/s40264-023-01302-7 (2023).","journal-title":"Drug Saf."},{"issue":"12","key":"19717_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0144263","volume":"10","author":"M Hashiguchi","year":"2015","unstructured":"Hashiguchi, M. et al. Factors affecting the timing of signal detection of adverse drug reactions. PLoS One. 10 (12), 1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0144263 (2015).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19717-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T03:25:20Z","timestamp":1760844320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19717-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19717-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35880"}}